Please login to the form below

Not currently logged in
Email:
Password:

Avanir Pharmaceuticals appoints new president and CEO

Rohan Palekar succeeds Keith Katkin

US-based biopharmaceutical firm Avanir Pharmaceuticals has appointed Rohan Palekar as its new president and chief executive officer.

He will be responsible for overseeing the development of the company's pipeline of products for CNS disorders along with the commercialisation of its recently FDA-approved neurological product, Nuedexta.

Palekar joined Avanir as senior vice president and chief commercial officer in March 2012 and was promoted to executive vice president and chief operating officer three years later.

He has over 20 years of drug development and commercialisation experience, having previously worked as chief commercial officer for Medivation and in various senior management roles at Johnson & Johnson and Centocor.

Palekar replaces Keith Katkin who served as president and chief executive officer for Avanir from March 2007 and will continue on at the company as a member of its board of directors.

Katkin said: “After nearly a decade of serving as Avanir's president and chief executive officer, I am incredibly proud of what we have accomplished and how much we have grown, transitioning from a development to a commercial organisation.

“I am very pleased to be transitioning to this new role and handing the reins to Roham, a passionate and innovative leader who ... has made significant contributions since joining Avanir over three years ago.”

25th January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics